Adiponectin and insulin: molecular mechanisms of metabolic disorders

Uchasova E.G., Gruzdeva O.V., Belik E.V., Dyleva Yu.A.

Federal State Budgetary Scientific Institution Research Institute for Complex Issues of Cardiovascular Diseases 6, Sosnovy Blv., 650062, Kemerovo, Russian Federation

ABSTRACT

Adiponectin, the most common plasma adipocytokine, plays a crucial metabolic and anti-inflammatory role. With insulin resistance associated with obesity, an increase of adiponectin concentration, which leads to the activation of signaling pathways involved in the regulation of metabolism, occurs. Currently, adiponectin is being investigated as a potential therapeutic target for metabolic syndrome, although more research is required to understand the underlying mechanisms controlling its levels. In this review, we will examine the main mechanisms that control adiponectin levels in blood serum and its role in insulin-sensitizing effect, as well as evaluate the potential use of adiponectin and its receptors as a potential therapeutic target.

Keywords: adiponectin, insulin, adipocytes, obesity.

Conflict of interest. The authors declare the absence of obvious and potential conflicts of interest related to the publication of this article.

Source of financing. No funding was received.

For citation: Uchasova E.G., Gruzdeva O.V., Belik E.V., Dyleva Yu.A. Adiponectin and insulin: molecular mechanisms of metabolic disorders. Bulletin of Siberian Medicine. 2020; 19 (3): 188–197. https://doi.org: 10.20538/1682-0363-2020-3-188-197.

Адипонектин и инсулин: молекулярные механизмы реализации метаболических нарушений

Учасова Е.Г., Груздева О.В., Белик Е.В., Дылева Ю.А.

Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний (НИИ КПССЗ) Россия, 650002, г. Кемерово, Сосновый бул., 6

РЕЗЮМЕ

Адипонектин – самый распространенный адипоцитокин в плазме крови, который играет критическую метаболическую и противовоспалительную роль. При инсулинорезистентности, связанной с ожирением, происходит увеличение концентрации адипонектина, что приводит к активации сигнальных путей, участвующих в регуляции метаболизма. В настоящее время адипонектин исследуется в качестве потенциальной терапевтической мишени для метаболического синдрома, хотя необходимы дополнительные исследования, чтобы понять основные механизмы, контролирующие уровень адипонектина в крови. В этом обзоре мы представим основные механизмы, контролирующие уровень адипонектина в сыворотке крови, и его роль в
INTRODUCTION

Adiponectin is one of the most studied adipocytokines. Since the discovery of adiponectin in adipose tissue, it has been shown that it can be secreted in skeletal muscle, osteoblasts, and lymphocytes [1, 2]. Nevertheless, adipose tissue remains the main source of adiponectin in the serum, and its concentration in the serum varies from 2 to 26 μg/ml, making up > 0.01% of serum protein [3, 4, 5].

In the last few years, the relationship between adiponectin and insulin has been widely studied since the sensitizing effect of adiponectin on insulin by binding to its receptors leads to the activation of adenosine monophosphate-activated protein kinases (AMPK), receptors activated by peroxisome proliferators (PPAR-α) and, possibly, other molecular ways which have not been studied; therefore, it is necessary to research it further. With insulin resistance (IR) associated with obesity, the content of adiponectin decreases, which leads to the activation of signaling pathways that regulate metabolism [3, 4]. At the same time, there is insufficient data on the effect of insulin on serum adiponectin levels and its receptors as a therapeutic target in cardiovascular diseases (CVD) was considered.

THE PRIMARY STRUCTURE OF ADIPONECTIN

Adiponectin is a glycoprotein [6] encoded by a single gene transcript and consisting of 247 amino acids. It has an N-terminal signal peptide (~28–32 amino acids) followed by a hypervariable region (12 amino acids) containing conservative amino acids necessary for oligomerization and a collagen region containing 22 Gly-X-Y repeats where X and Y are most often proline, isoleucine, or hydroxylysine (66 amino acids) and the C-terminal globular domain, which makes up 55% (136–137 amino acids) of the total number of amino acids [7]. Interestingly, the globular domain of adiponectin is a structural homolog to TNFα. However, despite the structural homology, there are not so many homologous sequences, with the exception of the four conservative residues responsible for maintaining structural folds. The collagen domain of adiponectin has a common homology with the complement protein C1q [7]. Thus, adiponectin belongs to the paralogous protein family known as C1Q/TNF-linked proteins or CTRPs [7].

MULTIMERIC FORMS OF ADIPONECTIN (OLIGOMERIZATION)

Serum adiponectin exists in several oligomeric complexes: trimer (LMW or low molecular weight form), hexamer (MMW or medium molecular weight form), and a 12- or 18-measure form (HMW or high molecular weight form) [7, 8]. In addition to these forms of adiponectin, there is a small form called gAd (globular adiponectin). The gAd mainly consists of 3 C-terminal globular domains held together by the strong hydrophobicity of the inner trimmer core [8]. It has been suggested that the HMW-adiponectin can also serve as a form of gAd storage that can be obtained from HMW [9].

The existence of multiple oligomeric structures contributes to the multifaceted activity of adiponectin, so that different oligomers act on different target tissues with diverse biological effects. The HMW adiponectin acts on liver and reduces the level of glucose in the blood serum, while the LMW or MMW adiponectin does not have similar effects [10].

Бюллетень сибирской медицины. 2020; 19 (3): 188–197
oligomer is necessary for the sensitizing effect of adiponectin on insulin by inhibiting gluconeogenesis in the liver [7]. On the other hand, gAd enhances fatty acid oxidation and insulin sensitization in skeletal muscles [11, 12]. In cultured myotubes, C2C12 HMW and MMW adiponectin activate NF-κB; while the trimer form activates AMPKα [13, 14]. On the contrary, Hada et al. showed that HMW adiponectin binds well to the membrane fraction of C2C12 muscle tubes [15]. In the central nervous system, HMW oligomers (large sizes) do not cross the blood-brain barrier. Thus, the main actions of adiponectin are mediated only by trimer and hexamer oligomers.

It is noteworthy that exogenous oligomers of adiponectin do not undergo conversion in blood serum to other oligomeric forms [16]. It has been proven that the intracellular production of oligomers is crucial to maintaining their serum ratio. Moreover, the affinity of binding of various adiponectin oligomers to its receptors, as well as the tissue-specific distribution of receptors, apparently contribute to the differentiated action of adiponectin [17].

**RECEPTORS OF ADIPONECTIN**

AdipoR1 (Adiponectin Receptor 1) and AdipoR2 (Adiponectin Receptor 2) belong to the PAQR family (family of progestin and adiponectin, C1Q and collagen domain containing) receptors), consisting of 7 transmembrane domains similar to G-protein coupled receptors (GPCR). However, unlike GPCR, adipoR is not associated with the G-protein and has an extracellular C-terminus and an intracellular N-terminus [18]. Skeletal muscles are the main tissue expressing AdipoR1, and liver cells express primarily AdipoR2. In addition, AdipoR1 and AdipoR2 bind to oligomeric forms of adiponectin with different affinities, for example, gAd mainly binds to AdipoR1, while full-sized adiponectin mainly binds to AdipoR2 [18]. Then, activation of intracellular signaling pathways occurs after binding to the receptor, which leads to the appearance of various physiological effects.

**PROTEINS INTERACTING WITH ADIPONECTIN RECEPTORS**

It is known that AdipoR1 and AdipoR2 do not have their own kinase/phosphorylating activity. Mutagenesis of intracellular tyrosine residues, which usually act as initiator signaling residues in other receptors, does not block adiponectin signaling [19]. So far, APPL1 (an adapter protein containing the homologous domain of plextrin), ERp46 (endoplasmic reticulum protein 46), Rack1 (receptor for activation of C-kinase 1) and CK2β (casein kinase 2β) have been identified for direct interaction with AdipoRs (Fig. 1).

**APPL1 protein** was identified as an adapter protein that binds to AdipoR, acting on both AdipoR1 and AdipoR2 to facilitate intracellular signaling. Binding of the ligand to AdipoR1 enhances the relationship of AdipoR1-APPL1 [20]. Overexpression of APPL1 in C2C12 muscle tubes increases the basal and adiponectin-induced phosphorylation of AMPK, p38 and ACC (acetyl-CoA carboxylase), which mediates the meta-
bolic functions of adiponectin. Accordingly, APPL1 knockout has been shown to inhibit AdipoR1-mediated signaling [21].

APPL2 is an isoform of APPL1 with 54% sequence similarity and similar domain organization. It acts as an inhibitor of APPL1 activity [22]. In addition, it is able to communicate with AdipoR through its BAR (Bin/Amphiphysin/Rvs) domain. Transgenic expression of APPL2 prevents the binding of APPL1-AdipoR1, which occurs either by competition of APPL1 for binding to AdipoR1, or by the formation of a heterodimer with APPL1, thereby inhibiting the interaction of APPL1-AdipoR1. Suppression of APPL2 expression improves adiponectin-induced fatty acid oxidation and glucose uptake [19]. APPL1 also enhances eNOS activation and NO production in endothelial cells by blocking direct competition the compound Akt (a signal intermediate in the signaling pathway of insulin with its endogenous inhibitor 3 (TRB3)). In adipocytes and muscle cells, APPL1 forms a complex with Akt2, which dissociates when stimulated by insulin to regulate insulin-stimulated translocation of the GLUT4 membrane. APPL1 also facilitates the binding of IRS1/2 to the insulin receptor.

**INTERMEDIATE SIGNAL MOLECULES**

**LKB1** (liver b1-kinase): after activation by ligand-bound AdipoR1 in the cytoplasm, APPL1 interacts and activates PP2A (phosphatase 2A protein). Activated PP2A deactivates PKC (protein kinase C) through dephosphorylation (threonine 410). PKC is a serine/threonine kinase that phosphorylates LKB1 to serine (307) and promotes its nuclear translocation. Deactivation of PKC leads to the accumulation of LKB1 in the cytoplasm, and also increases its interaction with APPL1. In the cytoplasm, APPL1 binds LKB1 and phosphorylates AMPK [22].

**CaMKK** (calcium/calmodulin dependent kinase kinase) has significant sequence and structural homology with LKB1 [23]. There are two CaMKK isoforms: CaMKKa and CaMKKB. They are encoded by two different genes and have 70% amino acid sequence homology. Adiponectin has been shown to enhance the production of cytoplasmic Ca^{2+} either by releasing Ca^{2+} from the sarcoplasmic reticulum, or by an extracellular influx of Ca^{2+} [24]. Unlike LKB1, CaMKK-mediated phosphorylation of AMPK depends only on Ca^{2+} [25]. In addition, in an experimental study performed on mice knocked out by AdipoR1, Iwabu et al. demonstrated that binding of AdipoR1 to the ligand induces Ca^{2+} influx and activates CaMKKB, which leads to AMPK phosphorylation [26].

**AMPK** is a serine/threonine protein kinase, also called a metabolic cell sensor. Functional AMPK protein is a heterotrimer consisting of α, β and γ subunits. The catalytic α subunit also has a threonine phosphorylation site (172), while β- and γ- subunits act as regulators. The α subunit has two options: α1 (is exclusively cytoplasmic) and α2 (localized in the nucleus). In addition to the kinases listed above (LKB1 and CaMKKB), AMPK is also activated by allosteric binding of AMP, the cellular level of which increases in a state of energy depletion [27].

Adiponectin induces AMPK activation in major peripheral target tissues. AdipoR1-mediated phosphorylation of AMPK was shown to inhibit skeletal muscle glycogen synthesis [28]. It is likely that the inhibition is due to phosphorylation of glycogen synthase to serine (7) only with AMPK α2 [29]. AMPK can also phosphorylate and activate PGC1α, receptors activated by peroxisome proliferators γ-coactivator 1α [30]. There are also data on an alternative pathway for PGC1α activation by adiponectin, including deacetylation of PGC1α through activation of sirtuin 1 (SIRT1). Subsequently, sirtuin 1-mediated activation of PGC1α activates gluconeogenic genes and hepatic glucose level, as well as PGC1α-mediated inhibition of glycolysis [31]. Activated CaMKKB can also activate PGC1α independently of AMPK [31]. In addition, activated PGC1α enhances mitochondrial biogenesis and mitochondrial respiration, which consequently enhances muscle fatty acid oxidation [31].

Activated AMPK also induces the translocation of the insulin-dependent glucose transporter GLUT4 (type 4 glucose transporter) to the cell surface of various cell types, including skeletal muscles, adipocytes and cardiomyocytes, thereby increasing glucose uptake, which is one of the insulin-sensitizing effects of adiponectin. S.L. Torn et al. proposed a GLUT4 translocation model in which AMPK was activated directly or via mTOR the AS160 inactivation pathway (substrate for Akt protein kinase 160 kDa), similar to the one transmitting insulin signals [32], thereby initiating GLUT4 translocation to the cell surface [33]. Moreover, through AMPK-mediated Rheb phosphorylation (Ras homolog), adiponectin inhibits the p70 S6 kinase, which is unable to phosphorylate serine (302) and activate IRS1 (insulin receptor substrate 1). Finally, this contributes to the insulin-sensitizing effect of adiponectin [34].
The addition of various oligomeric forms of adiponectin (HMW or LMW) to the culture medium containing hepatocytes leads to a decrease in glucose production in the medium due to transcriptional suppression of G6P (glucose 6 phosphate) and PEPCK (phosphoenolpyruvate carboxylase), which is responsible for gluconeogenesis and glycogenolysis, respectively, via the AMPK dependent mechanism [35]. In addition, data appeared on the independent inhibition of LKB1-AMPK gluconeogenesis [35].

AMPK signaling also activates autophagy by phosphorylation of Ulk1 (Unc-51-like kinase 1 or a kinase that initiates mammalian autophagy) under conditions of nutrient deficiency, i.e. serine (317) and serine (777). Moreover, AMPK phosphorylates and thereby deactivates mTOR (mammalian rapamycin target), which is a known inhibitor of autophagy. In nutrient-rich environments, mTOR inhibits the induction of autophagy by phosphorylating serine (757) Ulk1, thereby preventing AMPK binding and subsequent activation of Ulk1 [36]. Adiponectin was shown to induce autophagy in an AMPK-dependent manner in various cell types, including cardiomyocytes and skeletal muscle [37]. It also induces the differentiation of vascular smooth muscle cells through AMPK-mediated inhibition of the mTOR complex [38]. It is noteworthy that autophagy is an important mechanism for the differentiation of cells of various types [38].

**p38 MAPK:** APPL1 acts as an anchor for adiponectin-mediated activation of the p38 MAPK pathway. In experimental studies, it was shown that p38-MAPK and signal components of the cascade were combined using APPL1. Under basal conditions, TAK1 (transforming growth factor β-activated kinase) is found with APPL1, while MKK3 (MAP kinase-3) and p38 MAPK remain weakly bound to APPL1 [38]. Adiponectin-activated APPL1 further activates TAK1, and subsequently a complex consisting of MAPK AdipoR1, APPL1, TAK1, MKK3 and p38 is formed. Activated TAK1 then phosphorylates MKK3, which in turn phosphorylates p38 MAPK. After phosphorylation, MKK3 and TAK1 dissociate from APPL1, and TAK1 activity rapidly decreases. TAK1 can also directly phosphorylate AMPK. It was also shown that activated p38 MAPK has an antilipogenic effect on muscles [40].

**PPAR** activates ACO (acetyl CoA oxidase) and UCPs (uncoupling proteins), which ultimately promotes the fatty acid oxidation and increased energy expenditure in skeletal muscles [41]. PPARα signaling increases the sensitivity of hepatic insulin and therefore improves glucose uptake in the liver [41]. PPAR-mediated signaling also activates catalase and SOD1 (type 1 superoxide dismutase) in hepatocytes, which additionally contributes to the insulin-sensitizing effect of adiponectin in the liver by reducing oxidative stress [41]. On the other hand, PPARγ, which induces adiponectin expression in adipose tissue, is also activated by adiponectin [41].

**INSULIN-SENSITIZING EFFECT OF ADIPONECTIN**

Adiponectin has a sensitizing effect on insulin and other beneficial metabolic effects, inhibiting hepatic gluconeogenesis and enhancing fatty acid oxidation by activating AMP-activated protein kinase (AMPK) and proliferator-activated peroxisome α receptor (PPARα) [42, 43], as well as inhibition of acetyl-coenzyme A-carboxylase (ACC) in the liver and muscles [44]. Moreover, its anti-inflammatory effect is due to a decrease in the migration of macrophages and foam cells through the vascular wall and the polarization of macrophages [44]. A study by Fu et al. showed that overexpression of adiponectin in adipocytes increases insulin sensitivity by modulating proliferation, differentiation, and lipid accumulation [45].

With obesity, there is an active growth in adipose tissue: hyperplasia and hypertrophy. In response to energy balance, adipocytes produce and secrete various peptides. Studies have shown that adiponectin is a potential key mediator of glucose homeostasis in obesity and IR [46]. However, the autocrine actions and functions of adiponectin for adipocyte insulin signaling and glucose transport are not fully understood. In an experimental study, Chang et al. added insulin to a culture medium containing adipocytes, which induced a decrease in adiponectin mRNA expression [47]. In turn, adiponectin deficiency in the culture medium led to a decrease in insulin-stimulated glucose uptake and a decrease in the activation of AMPK in insulin-sensitive adipocytes.

At present, it is known that IRS proteins are of the greatest importance for insulin signal transmission; IRS-1 and IRS-2 are expressed in almost all types of cells and tissues [43]. IRS-1 mediates the regulatory effects of insulin on peripheral metabolic and growth processes, while IRS-2 is more responsible for the central effects of insulin, including control of differentiation and growth of neuronal cells, central regulation of eating behavior, glucose homeostasis and endocrine functions. It has been proven that a decrease in the content of IRS-1 is associated with IR and T2DM.
In addition, Yamauchi et al. found that administration of globular adiponectin to lipotropic mice improved insulin sensitivity by enhancing the insulin-stimulated tyrosine phosphorylation of IRS-1 [43]. In C2C12 myotubes, adiponectin treatment reduces the IRS-1 phosphorylation to serine (636/639), which inhibits the subsequent insulin-stimulated IRS-1 tyrosine phosphorylation using the insulin receptor. It was proved that the presence of IR leads to a change in the expression of GLUT4 in the plasma membrane and intracellular compartments of adipocytes with a deletion of the adiponectin gene [49].

AKT (protein kinase B), the next target for insulin signaling in the cell, also causes various metabolic effects mediated by insulin, and AKT activity has been shown to decrease markedly in T2DM [50]. In their study, Chang et al. showed that the addition of insulin to a culture medium containing adipocytes is accompanied by activation of AKT. However, the adiponectin deletion did not lead to further AKT activation compared to control cells transfected with siRNAs (a double-stranded RNA class, 20–25 nucleotides long) [47].

These results suggest that AKT signaling is not involved in adiponectin-induced reduction in insulin-stimulated glucose transport. GLUT 4 plays a key role in this process, which is involved in the clearance of glucose, and GLUT1 plays a secondary role, mainly for glucose uptake during non-insulin stimulation [50]. In IR conditions, including obesity and T2DM (type 2 diabetes mellitus), the expression of GLUT4 in adipocytes decreases [50]. Overexpression of GLUT4 in adipose tissue leads to an increase in glucose tolerance [50].

It should be noted that the expression of AdipoR1/R2 in insulin target tissues appears to be inversely correlated with plasma insulin levels, since insulin negatively regulates adiponectin receptor expression levels via the PI3 kinase/Foxo1 pathway. Thus, it is both AdipoR1/R2 agonism and strategies to increase AdipoR1/R2 that can be logical approaches to provide a new method for the treatment of IR and T2DM, as we have shown that in patients with visceral obesity in the late post-infarction period manifestation of T2DM [52].

It is also known that adiponectin indirectly regulates insulin sensitivity by modulating immune responses. It is noteworthy that adiponectin has an antiapoptotic effect on cardiomyocytes and β-cells of the pancreas and reduces oxidative stress in endothelial cells [43]. Despite these well-known endocrine effects of adiponectin, its autocrine/paracrine effects are still to be further researched. For example, adiponectin reduces ceramide in the liver by enhancing their catabolism and the production of the antiapoptotic metabolite sphingosine-1-phosphate (S1P), thereby improving insulin sensitivity, inhibiting inflammation. However, the role of adiponectin in controlling fatty ceramides is unclear. Overexpression of adiponectin in the adipose tissue of ob/ob mice reduces the thickness of AT and systemic inflammation and promotes the accumulation of fat in subcutaneous fatty deposits, including smaller adipocytes, which leads to improved sensitivity to systemic insulin and pancreatic β-cell survival [43]. However, the physiological effect of endogenous adiponectin derived from adipocytes on AT is not known.

When studying the molecular mechanisms underlying the insulin-sensitizing effect of adiponectin, there is growing evidence that adiponectin activates intracellular signaling pathways by activating AMPK and p38MAPK in skeletal muscle cells [53]. Stimulation of glucose utilization and fatty acid oxidation by adiponectin is mediated by AMPK and p38MAPK [44]. An increased expression of AMPK in C2C12 myotubes reduces the insulin-sensitizing effect of adiponectin [44]. In addition, blocking of the AMPK pathway inhibits adiponectin-induced insulin-sensitizing effects [54]. Thus, at present, the insulin-sensitizing effects of adiponectin have been studied only on peripheral tissues such as muscles and liver. It has been proven that a deletion of the adiponectin gene impairs insulin signaling simultaneously with a decrease in AMPK activation in insulin-sensitive, but not insulin-resistant, adipocytes. However, the autocrine effects of adiponectin on glucose uptake by adipocytes and insulin signaling have not been fully elucidated.

ADIPONECTIN AND ITS RECEPTORS AS A THERAPEUTIC TARGET IN CVD AND T2DM

Several strategies are considered to enhance the beneficial effects of adiponectin, including increasing both its plasma level and its activity. The levels of circulating adiponectin can be increased either by directly using exogenous adiponectin, for example, by injection, or by increasing endogenous adiponectin through treatment. Due to a high level of circulating blood and multimeric conformations of adiponectin, the direct use of exogenous adiponectin is difficult. Thus, increasing the level of endogenous adiponectin through the use of pharmacological agents, nutraceutical compounds and lifestyle modifications remains
the best option. Pharmaceutical products effective to increase circulating adiponectin include PPAR-α thiazolidinedione (TZD) agonists, renin-angiotensin inhibitors such as angiotensin converting enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blockers (ARBs) [55, 56].

In addition, the effect of statins is being actively discussed, and so recently we have shown that early use of statins in patients with MI leads to a significant increase in adiponectin levels and the adiponectin/leptin ratio, which is considered as a favorable effect of atorvastatin, which helps to reduce adipokine imbalance, normalize lipid exchange and reduce IR [57].

Among nutraceutical compounds, fish oil, linoleic acid, green tea extract, polyphenol resveratrol and osmotin, a representative of plant defense proteins, have recently been identified as potential adiponectin receptor agonists that can increase the concentration of adiponectin [58]. In addition, weight loss or physical activity can increase adiponectin levels, especially among people with obesity or diabetes [58].

An alternative approach to enhancing the beneficial effects of adiponectin is to enhance its transmission through compounds that may affect AdipoR. Treatment with PPARγ agonists, such as pioglitazone and rosiglitazone, increases plasma adiponectin levels and also increases insulin sensitivity in patients with IR and diabetes [58]. In addition, treatment with pioglitazone increases plasma adiponectin levels. Lin et al. showed that administration of rosiglitazone increases adiponectin mRNA levels in differentiated 3T3-L1 adipocytes for 1 day [59].

It has also been shown that insulin negatively regulates the HMW adiponectin complex. Accordingly, thiazolidinedione (TZD) mediated improvement in insulin sensitivity correlated with HMW concentration of adiponectin [59]. Although TZD is a widely used class of antidiabetic drugs, most patients do not show an improvement in insulin sensitivity [49]. The mechanism by which TZD stimulates an increase in adiponectin levels is unknown, but the secretory pathway of adipocytes appears to be the main site of action.

Pharmacological activation of AMPK by metformin has therapeutic potential for eliminating metabolic disorders, such as T2DM and non-alcoholic fatty liver disease. AMPK directly phosphorylates enzymes and transcription factors involved in the absorption of glucose and fatty acids and their mitochondrial metabolism by switching catabolic pathways [60]. It also disables the synthesis of glucose, glycogen and lipids in the liver through anabolic pathways and promotes the absorption of glucose in the muscles. It is also reported that metformin improves insulin sensitivity by activating AMPK, thereby inhibiting the synthesis of fatty acids and triglycerides and promoting fat oxidation [61].

CONCLUSION

Over the last few years, adiponectin has been of greatest clinical interest due to its positive regulatory effect in certain conditions, including IR. Some of the problems associated with the molecular and cellular mechanisms underlying the functioning of the insulin-adiponectin system can be taken into account as potentially useful in the development of new pharmacological approaches. Further study of the effect of insulin on adipokines is needed to fully elucidate the molecular mechanisms of biosynthesis, secretion and signal transduction and their potential therapeutic value.

REFERENCES

1. Maeda K. CDNA Cloning and expression of a novel adipose specific collagen-like factor, apM1 (dioseost Abundant Gene Transcript 1). Biochem. Biophys. Res. Commun. 2012; 425 (3): 556–559. DOI: 10.1016/j.bbrc.2012.08.023.
2. Liu Y., Sweeney G., Adiponectin action in skeletal muscle. Best Pract. Res. Clin. Endocrinol. Metab. 2014; 28 (1): 33–41. DOI: 10.1016/j.beem.2013.08.0034.
3. Crawford L.J.A., Peake R., Price S., Morris T.C.M., Irvine A.E. Adiponectin is produced by lymphocytes and is a negative regulator of granulopoiesis. J. Leukoc. Biol. 2010; 88 (4): 807–811. DOI: 10.1189/jlb.1109723.
4. Akingbemi B.T. Adiponectin receptors in energy homeostasis and obesity pathogenesis. Prog. Mol. Biol. Transl. Sci. 2013; 114: 317–342. DOI: 10.1016/B978-0-12-386933-3.00009-1.
5. Bespalova I.D., Ryazantseva N.V., Kalyuzhin V.V., Osiskhov L.A., Murashev B.Y., Medyantsev Y.A., Rudnitsky V.A. Gender features of the relation of hormonal activity adipose tissue and pro-inflammatory status in hypertension with metabolic syndrome. Bulletin of Siberian Medicine. 2014; 13 (5): 12–19. DOI: 10.20538/1682-0363-2014-5-12-19 (in Russ.).
6. Wang Y., Lu G., Wong W.P.S., Vliegenthart J.F.G., Gerwig G.J., Lam K.S.L., Cooper G.J., Xu A. Proteomic and functional characterization of endogenous adiponectin purified from fetal bovine serum. Proteomics. 2004; 4 (12): 3933–3942. DOI: 10.1002/pmic.200408026.
7. Wang Y., Lam K.S., Yau M.H., Xu. A. Post-translational modifications of adiponectin: mechanisms and functional implications. Biochem. J. 2008; 409 (3): 623–633. DOI: 10.1042/BJ20071492.
8. Waki H., T. Yamauchi, J. Kamon, S. Kita, Y. Ito, Y. Hada, Uchida S., Tsuchida A., Takekawa S., Kadowaki T. Generation of globular fragment of adiponectin by leukocyte elastase se-

Bulletin of Siberian Medicine. 2020; 19 (3): 188–197
10. Pajvani U.B., Hawkins M., Combs T.P., Rajala M.W., Halberg N., Schraw T.D., Wang Z.V., Kim J.Y., Yi J., Hamilton M.P., Luby-Phelps K., Scherer P.E. Systemic fate of the adipocyte-derived factor adiponectin. *Diabetes*. 2009; 58 (9): 1961–1970. DOI: 10.2337/db08-1750.

11. Wang Y., A. Xu, C. Knight, L.Y. Xu, Cooper G.J.S. Hydroxylation and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin. Potential role in the modulation of its insulin-sensitizing activity. *J. Biol. Chem.* 2002; 277 (22): 19521–19529. DOI: 10.1074/jbc.M2006100.200.

12. Fruebis J., Tsao T.S., Javorschi S., Ebbets-Reed D., Erickson M.R.S., Yen F.T., Bihain B.E., Lodish H.F. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. *Proc. Natl. Acad. Sci. USA.* 2001; 98 (4): 2005–2010. DOI: 10.1073/pnas.98.4.2005.

13. Tsao T.S.S., Murrey H.E., Hug C., Lee D.H., Lodish H.F. Oligomerization state-dependent activation of NF-κB signaling pathway by adipocyte complement-related protein of 30 kDa (Acrp30). *J. Biol. Chem.* 2002; 277 (33): 29359–29362. DOI: 10.1074/jbc.C2003122.000.

14. Tsao T.S., Tomas E., Murrey H.E., Hug C., Lee D.H., Ruderman N.B., Heuser J.E., Lodish H.F. Role of disulfide bonds in Acrp30/Adiponectin structure and signaling specificity: different oligomers activate different signal transduction pathways. *J. Biol. Chem.* 2003; 278 (50): 50810–50817. DOI: 10.1074/jbc.M3009469.200.

15. Hada Y., Yamauchi T., Waki H., Tsuchida A., Hara K., Miyazaki O., Ebinuma H., Kadowaki T. Selective purification of a 35-kDa (Acrp30) adiponectin: studies in human subjects and in experimental animals. *Eur. J. Endocrinol.* 2005; 153 (3): 409–417. DOI: 10.1530/eje.1.01978.

16. Pischon T., Hotamisligil G.S., Rimm E.B. Adiponectin: stability in plasma over 36 hours and within-person variation over 1 year. *Clin. Chem.* 2003; 49 (4): 650–652. DOI: 10.1373/49.4.650.

17. Tanabe H., Fujii Y., Okada-Iwabu M., Iwabu M., Nakamura Y., Hosaka T. Crystal structures of the human adiponectin receptors. *Nature*. 2015; 520 (7547): 312–316. DOI: 10.1038/nature14301.

18. Ruan H., Dong L.Q. Adiponectin signaling and function in insulin target tissues. *J. Mol. Cell. Biol.* 2016; 8: 101–109. DOI: 10.1093/jmcb/mjw014.

19. Mao X., Kikani C.K., Riojas R.A., Langlais P., Wang L., Ramos F.J., Fang Q., Christ-Roberts C.Y., Hong J.Y., Kim R.Y., Liu F., Dong L.Q. APPL1 binds to adiponectin receptors and mediates adiponectin signaling and function. *Nat. Cell Biol.* 2006; 8 (5): 516–523. DOI: 10.1038/ncb1404.

20. Buechler C., Wanninger J., Neumeier M. Adiponectin receptor binding proteins – recent advances in elucidating adiponectin signaling pathways. *FEBs Lett.* 2010; 584 (20): 4280–4286. DOI: 10.1016/j.fsl.2010.09.035.

21. Deepa S.S., Zhou L., Ryu J., Wang C., Mao X., Li C., Zhang N., Musi N., DeFranzo R.A., Liu F., Dong L.Q. APPL1 mediates adiponectin-induced LKB1 cytosolic localization through the PP2A-PKCζeta signaling pathway. *Mol. Endocrinol.* 2011; 25 (10): 1773–1785. DOI: 10.1210/me.2011-0082.

22. Gormand A., Henriksson E., Ström K., Jensen T.E., Sakamoto K., Göransson O., Regulation of AMP-activated protein kinase by LKB1 and CaMKK in adipocytes. *J. Cell. Biochem.* 2011; 112: 1364–1375. DOI: 10.1002/jcb.23053.

23. Woods A., Dickerson K., Heath R., Hong S.P., Momcilovic M., Johnston S.R., Carlson M. Carling D. Ca2+/calmodulin-dependent protein kinase kinase (calmodulin-dependent protein kinase-β) acts upstream of AMP-activated protein kinase in mammalian cells. *Cell Metab.* 2005; 2 (1): 21–33. DOI: 10.1016/j.cmet.2005.06.005.

24. Zhou L., Deepa S.S., Etzler J.C., Ryu J., Mao X., Fang Q., Liu D.D., Torres J.M., Jia W., Lechleiter J.D., Liu F., Dong L.Q. Adiponectin activates AMP-activated protein kinase in muscle cells via APPL1/LKB1-dependent and phospholipase C/Ca2+/Ca2+/calmodulin-dependent protein kinase protein kinase dependent pathways. *J. Biol. Chem.* 2009; 284 (33): 22426–22435. DOI: 10.1074/jbc.M109.028357.

25. Iwabu M., Yamauchi T., Okada-Iwabu M., Sato K., Nakagawa T., Funata M. Adiponectin and AdipoR1 regulate PGC-1α and mitochondrion by Ca(2+) and AMPK/SIRT1. *Nature*. 2010; 464 (7393): 1313–1319. DOI: 10.1038/nature08991.

26. Kahn B.B., Alquier T., Carling D., Hardie D.G. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. *Cell Metab.* 2005; 1 (1): 15–25. DOI: 10.1016/j.cmet.2004.12.003.

27. Ceddia R.B., Somwar R., Maida A., Fang X., Bikopoulos G., Sweeney G. Globular adiponectin increases GLUT4 translocation and glucose uptake but reduces glycogen synthesis in rat skeletal muscle cells. *Diabetologia*. 2005; 48 (1): 132–139. DOI: 10.1007/s00125-004-1609-y.

28. Jørgensen S.B., Nielsen J.N., Birk J.B., Olsen G.S., Voutilainen E., Jouppila P., Sand ˚stro¨m F.J., Fang Q., Christ-Roberts C.Y., Hong J.Y., Kim R.Y., Liu F., Dong L.Q. APPL1 binds to adiponectin receptors and mediates adiponectin signaling and function. *Nat. Cell Biol.* 2006; 8 (5): 516–523. DOI: 10.1038/ncb1404.

29. Buechler C., Wanninger J., Neumeier M. Adiponectin receptor binding proteins – recent advances in elucidating adiponectin signaling pathways. *FEBs Lett.* 2010; 584 (20): 4280–4286. DOI: 10.1016/j.fsl.2010.09.035.

30. Deepa S.S., Zhou L., Ryu J., Wang C., Mao X., Li C., Zhang N., Musi N., DeFranzo R.A., Liu F., Dong L.Q. APPL1 mediates adiponectin-induced LKB1 cytosolic localization through the PP2A-PKCζeta signaling pathway. *Mol. Endocrinol.* 2011; 25 (10): 1773–1785. DOI: 10.1210/me.2011-0082.
through a complex of PGC-1α and SIRT1. *Nature.* 2005; 434 (7029): 113–118. DOI: 10.1038/nature03141.

32. Thorn S.L., Gorlof M.H., Harper M.E., Beanlands R.S., Dekemp R.A., Dasilva J.N. Chronic AMPK activity dysregulation produces myocardial insulin resistance in the human Arg302Gln-PRKAG2 glycosen storage disease mouse model. *EJNMMI Res.* 2013; 3(1): 48. DOI: 10.1186/2191-219X-3-48.

33. Stöckl J., Davey J.R., Hohrens-Behrens C., Xu A., James D.E., Ramm G. Regulation of glucose transporter 4 translocation by the Rab guanosine triphosphatase-activating protein AS160/TBC1D4: role of phosphorylation and membrane association. *Mol. Endocrinol.* 2008; 22 (12): 2703–2715. DOI: 10.1210/me.2008-0111.

34. Wang C., Mao X., Liu M., Wetzel M.D., Guan K.L. Adiponectin decreases lipids.

35. Combs T.P., Marliss E.B. Adiponectin signaling in the liver.

36. Kim J., Kundu M., Viollet B., Guan K.L. AMPK and mTOR

37. Gamberi T., Modesti A., Magherini F., Souza D.M.D.,...abrogation of adiponectin binding and metabolic actions.

38. Xie M., Zhang D., Dyck J.R.B., Li Y., Zhang H., Morishishi...scaffolding the TAK1-MKK3-p38 MAPK pathway.

39. Xie M., Zhang D., Dyck J.R.B., Li Y., Zhang H., Morishishi...scaffolding the TAK1-MKK3-p38 MAPK pathway.

40. Yan J., Lan G., Qi R., Sun C. Adiponectin decreases lipids deposition by p38 MAPK/ATF2 signaling pathway in muscle of broilers. *Mol. Biol. Rep.* 2013; 40 (12): 7017–7025. DOI: 10.1007/s11033-013-2821-y.

41. Yamauchi T., Nio Y., Maki T., Kobayashi M., Takazawa T., Iwabu M. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. *Nat. Med.* 2007; 13 (3): 332–339. DOI: 10.1038/nm1557.

42. Berg A.H., Combs T.P., Du X., Brownlee M., Scherer P.E. The adipocyte-secreted protein crp30 enhances hepatic insulin action. *Nat. Med.* 2001; 7 (8): 947–953. DOI: 10.1038/90992.

43. Yamauchi T., Kamon J., Waki H., Terauchi Y., Kubota N., Hara K. The fat-derived hormone adiponectin reverses insulino resistance associated with both lipatrophy and obesity. *Nat. Med.* 2001; 7 (8): 941–946. DOI: 10.1038/90994.

44. Yoon M.J., Lee G.Y., Chung J.J., Ahn Y.H., Hong S.H., Kim J.B. Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator-activated receptor a. *Diabetes.* 2006; 55 (9): 2562–2570. DOI: 10.2337/db05-1322.

45. Fu Y., Luo N., Klein R.L., Garvey W.T. Adiponectin promotes adipocyte differentiation, insulin sensitivity, and lipid accumulation. *J. Lipid. Res.* 2005; 46 (7): 1369–1379. DOI: 10.1194/jlr.M400373-JLR200.

46. Weyer C., Funahashi T., Tanaka S., Hotta K., Matsuzawa Y., Pratley R.E. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. *J. Clin. Endocrinol. Metab.* 2001; 86 (5):1930–1935. DOI: 10.1210/jc.86.5.7463.

47. Chang E., Choi J.M., Park S.E., Rhee E.J., Lee W.Y., Oh K.W., Park S.W., Park C.Y. Adiponectin deletion impairs insulin signaling in insulin-sensitive but not insulin-resistant 3T3-L1 adipocytes. *Life Sci.* 2015; 132: 93–100. DOI: 10.1016/j.lfs.2015.02.013.

48. Kern P.A., Di Gregorio G.B., Lu T., Rassouli N., Ranganathan G. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. *Diabetes.* 2003; 52 (7): 1779–1785. DOI: 10.2337/db02-7577.

49. Danielsson A., Ost A., Lystedt E., Kjolhede P., Gustavsson S., Nyström F.H., Strålfors P. Insulin resistance in human adipocytes occurs downstream of IRS1 after surgical cell isolation but at the level of phosphorylation of IRS1 in type 2 diabetes. *FERS J.* 2005; 272 (1): 141–151. DOI: 10.1111/j.1432-1033.2004.04396.x.

50. Pessin J.E., Saltiel A.R. Signaling pathways in insulin action: molecular targets of insulin resistance. *J. Clin. Invest.* 2000; 106 (2): 165–169. DOI: 10.1172/JCI10582.

51. Hammarstedt A., Graham T.B. Adipose tissue dysregulation and reduced insulin sensitivity in non-obese individuals with enlarged abdominal adipose cells. *Diabetol. Metab. Syndr.* 2012; 4 (1): 42. DOI: 10.1186/1758-5996-4-42.

52. Barbarash O., Gruzdeva O., Uchasova E., Belik E., Dyleva Y., Karetiknova V. Biochemical markers of type 2 diabetes as a late complication of myocardial infarction: a case-control study. *Archives of Medical Science.* 2017; 13(2): 311–320. DOI: 10.5111/amms.2017.65240.

53. Xin X., Zhou L., Reyes C.M., Liu F., Dong L.Q. APPL1 mediated adiponectin-stimulated p38 MAPK activation by scaffolding the TAK1-MKK3-p38 MAPK pathway. *Am. J. Physiol. Endocrinol. Metab.* 2011; 300 (1): 103–110. DOI: 10.1152/ajpendo.00427.2010.

54. Yamauchi T., Kamon J., Ito Y., Tsuchida A., Yokomizo T., Kita S.. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. *Nature.* 2001; 408: 113–118. DOI: 10.1038/nature00175.1.

55. Ghadge A.A., Harke S.M., Khadke S.P., Diwan A.G., Panikkari O.P., Ranjekar P.K., Kuvalekar A.A. Circulatory adipocytokines and lipid profile variations in type-2 diabetic subjects: desirable side-effects of antiabiotic
56. Wang Z.V., Scherer P.E. Adiponectin, cardiovascular function, and hypertension. *Hypertension*. 2008; 51 (1): 8–14. DOI: 10.1161/HYPERTENSIONAHA.107.099424.

57. Gruzdeva O., Uchasova E., Dyleva Y., Karetnikova V., Barbarash O., Akbasheva O. Early effects of treatment low-dose atorvastatin on markers of insulin resistance and inflammation in patients with myocardial infarction. *Frontiers in Pharmacology*. 2016; 7: 324. DOI: 10.3389/fphar.2016.00324.

58. Rasouli N., Yao-Borengasser A., Miles L.M., Elbein S.C., Kern P.A. Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression. *Am. J. Physiol. Endocrinol. Metab*. 2006; 290: 42–46. DOI: 10.1152/ajpendo.00240.2005.

59. Lin W.S., Chang H.M., Tai T.Y., Chuang L.M. Effect of thiazolidinedione on gene expression in NIH3T3-L1 adipocytes (Abstract). *Diabetes*. 1999; 48 (1): 217.

60. Ghadge A.A., Khaire A.A., Kuvalekar A.A. Adiponectin: potential therapeutic target for metabolic syndrome. *Cytokine Growth Factor Rev*. 2018; 39: 151–158. DOI: 10.1016/j.cytofgr.2018.01.004.

61. Srivastava R.A.K., Pinkosky S.L., Filippov S., Hanselman J.C., Cramer C.T., Newton R.S. AMP-activated protein kinase: an emerging drug target to regulate imbalances in lipid and carbohydrate metabolism to treat cardio-metabolic diseases: thematic review series: new lipid and lipoprotein targets for the treatment of cardiometabolic diseases. *J. Lipid. Res.* 2012; 53 (12): 2490–2514. DOI: 10.1194/jlr.R025882.

Authors information

Uchasova Evgeniya G., Cand. Sci. (Med.), Senior Research Officer, Homeostasis Research Laboratory, Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russian Federation.

Gruzdeva Olga V., Dr. Sci. (Med.), Head of Homeostasis Research Laboratory, Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russian Federation.

Belik Ekaterina V., Research Officer, Homeostasis Research Laboratory, Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russian Federation.

Dyleva Yuliya A., Cand. Sci. (Med.), Senior Research Officer, Homeostasis Research Laboratory, Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russian Federation.

(✉) Uchasova Evgeniya G., e-mail: evg.uchasova@yandex.ru.

Received 07.02.2019
Accepted 25.12.2019